Question 1

What is Quizartinib?

Accepted Answer

Quizartinib works by interfering with the signaling pathways that allow cancer cells to multiply and survive. It belongs to a class of drugs called kinase inhibitors, which target specific enzymes involved in cell growth.

The medication specifically targets the FLT3 protein, which can be overactive or mutated in certain conditions. By inhibiting this protein, the drug helps to slow or stop the production of abnormal cells.

Question 2

What is Quizartinib used for?

Accepted Answer

Quizartinib is used to treat acute myeloid leukemia with FLT3-ITD mutation (with standard chemotherapy, including maintenance).

Question 3

How does Quizartinib work?

Accepted Answer

Targeting FLT3 Proteins

Quizartinib belongs to a class of medications called kinase inhibitors. It works by targeting and blocking a specific protein found on the surface of leukemia cells called Fms-like tyrosine kinase 3 (FLT3).

In a healthy body, the FLT3 protein helps regulate the production of blood cells. However, in some patients with acute myeloid leukemia (AML), the gene for this protein has a specific mutation called internal tandem duplication (ITD). This mutation causes the FLT3 protein to become overactive, sending constant signals to the leukemia cells to grow and divide uncontrollably.

How It Affects Cancer Cells

By binding to the mutated FLT3 protein, quizartinib interferes with these growth signals. This action helps to:

Stop or slow the proliferation of cancerous white blood cells.

Induce the death of leukemia cells that rely on the FLT3 signal to survive.

Because this medication targets a specific protein associated with a genetic mutation, it is considered a targeted therapy rather than a traditional chemotherapy that affects all rapidly dividing cells in the body.

Question 4

What are the brand names for Quizartinib?

Accepted Answer

Quizartinib is sold under the brand name Vanflyta .

Question 5

What are the active ingredients in Quizartinib?

Accepted Answer

The active ingredient in Quizartinib is quizartinib .

Question 6

What are the side effects of Quizartinib?

Accepted Answer

Common side effects of Quizartinib may include:

Nausea

Vomiting

Diarrhea

and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Quizartinib?

Accepted Answer

Quizartinib belongs to the FLT3 inhibitor drug class.

Question 8

What is the dosage of Quizartinib and how do I take it?

Accepted Answer

How to Take Quizartinib

Quizartinib is taken by mouth once daily at approximately the same time each day. It may be taken with or without food. Tablets must be swallowed whole and should not be crushed, broken, or chewed.

Missed Doses

If a dose is missed, it should be taken as soon as possible on the same day. If the missed dose is not remembered until the next day, skip that dose and resume the regular schedule. Do not take a double dose to make up for a missed one.

Vomiting

If vomiting occurs after taking a dose, do not take an extra dose. Continue with the next scheduled dose at the regular time.

Question 9

Is Quizartinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Quizartinib may cause fetal harm if taken during pregnancy. Animal studies indicate that the medication can lead to embryo-fetal toxicity, which may result in birth defects or pregnancy loss. Individuals who can become pregnant should typically have a pregnancy test to confirm they are not pregnant before starting this treatment.

Contraception Requirements

Because of the potential risks to a developing fetus, healthcare providers recommend strict adherence to birth control measures:

Females: Use effective contraception during treatment and for 7 months after the final dose.

Males: If you have a female partner who can become pregnant, use effective contraception during treatment and for 4 months after the final dose.

Breastfeeding

It is not known whether quizartinib passes into human breast milk. Because of the risk of serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least one month after the last dose. Patients should discuss the best way to feed their baby with a healthcare provider during this time.

Question 10

What forms and strengths does Quizartinib come in?

Accepted Answer

Quizartinib is currently available in the following form:

Oral Tablet: This medication is taken by mouth, usually once daily with or without food.

The tablets should be swallowed whole. Do not crush, chew, or break the tablets before swallowing.

Question 11

What is the FDA approval status of Quizartinib?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved quizartinib in July 2023. It is indicated for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by maintenance monotherapy, for adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive.

The presence of the FLT3-ITD mutation must be confirmed by an FDA-approved diagnostic test before treatment begins. Quizartinib is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

Boxed Warning and REMS

Quizartinib carries a Boxed Warning, the FDA's most serious warning, regarding the risk of QT prolongation, torsades de pointes, and cardiac arrest. Because of these life-threatening cardiac risks, the drug is only available through a restricted program called the Vanflyta Risk Evaluation and Mitigation Strategy (REMS).

Requirements of the REMS program include:

Healthcare providers who prescribe the medication must be certified in the program.

Pharmacies must be certified and may only dispense the drug to patients who are enrolled.

Healthcare settings must be certified to ensure appropriate monitoring and management of cardiac risks.

Pharmacogenomic Considerations

The FDA includes quizartinib in its table of pharmacogenomic biomarkers in drug labeling. The medication is specifically targeted for patients with the FLT3-ITD mutation, and its safety and efficacy have not been established in patients with other types of AML.

Question 12

What should I know about Quizartinib and fda approval?

Accepted Answer

The U.S. Food and Drug Administration (FDA) approved quizartinib in July 2023. It is specifically indicated for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) that tests positive for a genetic mutation known as FLT3 internal tandem duplication (ITD).

Quizartinib is approved for use in three distinct phases of AML treatment:

Induction: Used in combination with standard cytarabine and anthracycline chemotherapy.

Consolidation: Used in combination with cytarabine chemotherapy.

Maintenance: Used as a single-agent therapy following consolidation chemotherapy.

The FDA requires that the FLT3-ITD mutation be confirmed by an approved diagnostic test before treatment begins. Quizartinib is not indicated as a standalone treatment for the induction or consolidation phases of therapy.

Quizartinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Approval Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?